J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN, Int J Cancer, vol.127, pp.2893-917, 2008.

R. Adam, D. Gramont, A. Figueras, J. Guthrie, A. Kokudo et al., The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus, The Oncologist, vol.17, pp.1225-1264, 2012.

M. C. Niekel, S. Bipat, and J. Stoker, Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment, Radiology, vol.257, pp.674-84, 2010.

C. Deleau, B. Buecher, C. Rousseau, F. Kraeberbodéré, M. Flamant et al., Clinical impact of fluorodeoxyglucose-positron emission tomography scan/ computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence, Eur J Gastroenterol Hepatol, vol.23, pp.275-81, 2011.

E. Van-cutsem, A. Cervantes, B. Nordlinger, D. Arnold, and E. Group, Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, issue.3, pp.1-9, 2014.

D. V. Sahani, S. P. Kalva, A. J. Fischman, R. Kadavigere, M. Blake et al., Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and wholebody FDG PET, AJR Am J Roentgenol, vol.185, pp.239-285, 2005.

P. P. Mainenti, M. Mancini, C. Mainolfi, L. Camera, S. Maurea et al., Detection of colorectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents, Abdom Imaging, vol.35, pp.511-532, 2010.

R. M. Sharkey and D. M. Goldenberg, Novel radioimmunopharmaceuticals for cancer imaging and therapy, Curr Opin Investig Drugs, vol.9, pp.1302-1318, 2008.

F. Kraeber-bodéré, C. Rousseau, C. Bodet-milin, E. Frampas, A. Faivre-chauvet et al., A pretargeting system for tumor PET imaging and radioimmunotherapy, Front Pharmacol, vol.6, p.54, 2015.

C. D. Vrabie, M. Ceau?u, A. Petrescu, M. Waller, and D. I. , The usefulness of immunohistochemistry in sporadic colorectal cancer, Rom J Morphol Embryol, vol.49, pp.525-560, 2008.

E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, W. J. Mcbride, R. M. Sharkey et al., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc Natl Acad Sci, vol.103, pp.6841-6847, 2006.

D. M. Goldenberg, E. A. Rossi, R. M. Sharkey, W. J. Mcbride, and C. H. Chang, Multifunctional antibodies by the Dock-andLock method for improved cancer imaging and therapy by pretargeting, J Nucl Med, vol.49, pp.158-63, 2008.

R. Schoffelen, R. M. Sharkey, D. M. Goldenberg, G. Franssen, W. J. Mcbride et al., Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigenexpressing tumors with a bispecific antibody and a 68Gaand 18F-labeled hapten peptide in mice with human tumor xenografts, Mol Cancer Ther, vol.9, pp.1019-1046, 2010.

R. M. Sharkey, E. A. Rossi, W. J. Mcbride, C. H. Chang, and D. M. Goldenberg, Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy, Semin Nucl Med, vol.40, pp.190-203, 2010.

W. J. Mcbride, P. Zanzonico, R. M. Sharkey, C. Norén, H. Karacay et al., Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide, J Nucl Med, vol.47, pp.1678-88, 2006.

H. Karacay, R. M. Sharkey, W. J. Mcbride, G. L. Griffiths, Z. Qu et al., Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen, Bioconjug Chem, vol.13, pp.1054-70, 2002.

S. K. Woo, T. S. Lee, K. M. Kim, J. Y. Kim, J. H. Jung et al., Anesthesia condition for (18)F-FDG imaging of lung metastasis tumors using small animal PET, Nucl Med Biol, vol.35, pp.143-50, 2008.

D. S. Surasi, P. Bhambhvani, J. A. Baldwin, S. E. Almodovar, O. Malley et al., 18 F-FDG PET and PET/CT patient preparation: a review of the literature, J Nucl Med Technol, vol.42, pp.5-13, 2014.

R. M. Sharkey, H. Karacay, T. M. Cardillo, C. H. Chang, W. J. Mcbride et al., Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods, Clin Cancer Res, vol.11, pp.7109-7121, 2005.

D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J. F. Chatal, Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy, J Clin Oncol, vol.24, pp.823-857, 2006.

R. M. Sharkey and D. M. Goldenberg, Cancer radioimmunotherapy. Immunotherapy, vol.3, pp.349-70, 2011.

E. Frampas, C. Rousseau, C. Bodet-milin, J. Barbet, J. F. Chatal et al., Improvement of radioimmunotherapy using pretargeting, Front Oncol, vol.3, p.159, 2013.

G. L. Griffiths, C. H. Chang, W. J. Mcbride, E. A. Rossi, A. Sheerin et al., Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates, J Nucl Med, vol.45, pp.30-39, 2004.

E. Frampas, C. Maurel, P. Thedrez, R. Saëc, P. Faivre-chauvet et al., The intraportal injection model for liver metastasis: advantages of associated bioluminescence to assess tumor growth and influences on tumor uptake of radiolabeled anti-carcinoembryonic antigen antibody, Nucl Med Commun, vol.32, pp.147-54, 2011.

S. Hammarström, The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues, Semin Cancer Biol, vol.9, pp.67-81, 1999.

R. Schoffelen, O. C. Boerman, D. M. Goldenberg, R. M. Sharkey, C. M. Van-herpen et al., Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results, Br J Cancer, vol.109, pp.934-976, 2013.

R. Schoffelen, W. T. Van-der-graaf, R. M. Sharkey, G. M. Franssen, W. J. Mcbride et al., Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method, EJNMMI Res, vol.2, 2012.

A. Al-nahhas, Z. Win, T. Szyszko, A. Singh, C. Nanni et al., Gallium-68 PET: a new frontier in receptor cancer imaging, Anticancer Res, vol.27, pp.4087-94, 2007.

V. Ambrosini, D. Campana, P. Tomassetti, and S. Fanti,

, Ga-labelled peptides for diagnosis of gastroenteropancreatic NET, Eur J Nucl Med Mol Imaging, vol.39, 2012.

F. Kraeber-bodere, C. Bailly, M. Chérel, and J. F. Chatal, ImmunoPET to help stratify patients for targeted therapies and to improve drug development, Eur J Nucl Med Mol Imaging, vol.43, pp.2166-2174, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01809742

D. V. Gold, D. M. Goldenberg, H. Karacay, E. A. Rossi, C. H. Chang et al., A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma, Cancer Res, vol.68, pp.4819-4845, 2008.

C. M. Van-rij, S. Lütje, C. Frielink, R. M. Sharkey, D. M. Goldenberg et al., Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an antiTROP-2 x anti-HSG bispecific antibody, Eur J Nucl Med Mol Imaging, vol.40, pp.1377-83, 2013.

E. Frampas, C. Maurel, R. Saëc, P. Mauxion, T. Faivre-chauvet et al., Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide, Eur J Nucl Med Mol Imaging, vol.38, pp.2153-64, 2011.